內分泌檢測市場至2030年的預測：按檢測類型、技術、最終用戶和地區的全球分析

根據 Stratistics MRC 的資料，2023年全球內分泌檢測市場規模為 28 億美元，預計在預測期內年複合成長率為 10.4%，到2030年將達到 55 億美元。

內分泌測試評估人體內分泌系統中的荷爾蒙濃度。透過測量血液、尿液和唾液樣本中的荷爾蒙濃度，此診斷程序有助於識別荷爾蒙失衡和疾病。甲狀腺激素、皮質醇、胰島素、睪固酮和雌激素等生殖激素都是經常檢測的荷爾蒙。

根據世界衛生組織（WHO）2022年3月的資料，全球有6.5億成年人、3.4億青少年和3,900萬名兒童患有肥胖症，而且這一數字仍在持續成長。

與生活方式相關的疾病增加

內分泌相關疾病的增加部分是由於生活方式的改變，例如久坐的生活方式和不健康的飲食習慣。人們越來越需要能夠準確識別荷爾蒙失衡並提供此類疾病早期診斷的診斷測試。此外，內分泌檢測市場受到醫療專業人員的推動，他們尋求尖端設備來解決診斷文明病的挑戰，以及準確及時的激素評估以實現有效疾病治療的需求。由於對性別的重視，預計會出現成長。

檢體採集錯誤

正確的檢體採集、儲存和運輸對於確保準確的荷爾蒙濃度測量非常重要。檢體處理不當、污染和運輸延誤等問題可能會損害檢體的完整性並導致測試結果不準確。結果的差異也可能是由於使用不一致的資料收集方法的醫療保健環境的差異造成的。然而，為了保持內分泌檢測的準確性和一致性，必須解決與此類檢體相關的問題，並強調需要對醫療保健專業人員進行統一的程序和培訓。

伴同性診斷劑

伴同性診斷透過為內分泌疾病的個體化治療提供量身定做的解決方案，為內分泌檢測市場提供了獨特的機會。透過識別特定的生物標記或遺傳標記物，這些診斷可以幫助醫療專業人員為患者配對最合適的治療方法。這種精確的方法可以最大限度地減少副作用，最大限度地提高治療性介入，並改善內分泌檢測的結果。此外，這種客製化方法將提高內分泌相關醫療保健的整體有效性和經濟性，同時改善病患照護。

智慧財產權挑戰

智慧財產權問題源自於新測試、生物標記和診斷技術的創建和應用。花錢進行研發的公司必須擔心專利侵權，因為競爭對手可能會試圖模仿或增強自己的測試方法。內分泌診斷的動態性質引起了對現有專利的範圍和有效性的質疑，並引發了智慧財產權糾紛。

COVID-19 的影響：

內分泌檢測市場受到了 COVID-19 大流行的嚴重影響。由於內分泌系統是受病毒影響的器官之一，因此越來越需要內分泌檢測來評估感染者的荷爾蒙失衡和併發症。由於需要全面的診斷解決方案來了解病毒如何影響荷爾蒙濃度，內分泌檢測產業經歷創新和研究的激增。由於重點在於內分泌疾病的診斷和治療，儘管醫療保健系統受到干擾，但在這些困難時期，內分泌檢測市場仍持續成長。

免疫測量領域預計將成為預測期內最大的領域

由於荷爾蒙和相關生物標記鑑定的高靈敏度和特異性，免疫測量領域經歷顯著的成長。內分泌疾病（包括糖尿病和甲狀腺問題）的日益普及推動了對準確有效的診斷技術的需求。此外，自動化、新檢測方法的開發和技術的發展也促進了這一領域的成長。

胰島素檢測領域預計在預測期內年複合成長率最高

預計胰島素測試領域在預測期內年複合成長率最高。胰島素檢測的需求量很大，因為糖尿病管理很大程度上依賴監測胰島素濃度。該領域的發展也得益於測試技術的進步，包括更快、更準確的檢測。胰島素檢測的採用也受到對個人化醫療和糖尿病早期檢測的日益重視的影響。

佔有率最大的地區

由於內分泌疾病盛行率不斷上升、荷爾蒙健康意識不斷增強以及醫療基礎設施的進步，亞太地區所佔佔有率最大。最新診斷技術的採用和醫療保健設施的擴張促進市場的成長。此外，不斷增加的研發投入和政府的積極措施也進一步推動了市場的擴張。

年複合成長率最高的地區：

由於北美內分泌疾病盛行率不斷上升以及公眾對疾病早期檢測的意識不斷增強，該市場見證盈利成長。該地區高額的醫療保健支出和發達的醫療基礎設施進一步推動了市場的成長。此外，生物技術和製藥行業研發支出的增加推動內分泌檢測技術的創新，進一步推動該地區的成長。

免費客製化服務：

訂閱此報告的客戶將收到以下免費自訂選項之一：

• 公司簡介
  • 其他市場參與者的綜合分析（最多3家公司）
  • 主要企業SWOT分析（最多3家公司）
• 區域細分
  • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
• 競爭基準化分析
  • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

• 概述
• 相關利益者
• 調查範圍
• 調查方法
  • 資料探勘
  • 資料分析
  • 資料檢驗
  • 研究途徑
• 調查來源
  • 主要調查來源
  • 二次調查來源
  • 先決條件

第3章 市場趨勢分析

• 促進因素
• 抑制因素
• 機會
• 威脅
• 技術分析
• 最終用戶分析
• 新興市場
• 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

• 供應商的議價能力
• 買方議價能力
• 替代品的威脅
• 新進入者的威脅
• 競爭公司之間的敵對關係

第5章 全球內分泌檢測市場：依檢測類型

• 人類絨毛膜促性腺激素分泌檢測
• 催乳素測試
• 黃體酮測試
• 胰島素測試
• 甲狀腺刺激素測試
• 黃體激素測試
• 硫酸磊晶試驗
• 雌二醇試驗
• 皮質醇測試
• 睪酮測試
• 濾泡刺激素測試
• 其他測試類型

第6章 全球內分泌檢測市場：依技術分類

• 基於核酸的
• 質譜
• 層析法
• 免疫檢測
• 其他技術

第7章 全球內分泌檢測市場：依最終用戶分類

• 臨床實驗室
• 診斷中心
• 醫院
• 其他最終用戶

第8章 全球內分泌檢測市場：依地區

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 紐西蘭
  • 韓國
  • 其他亞太地區
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 卡達
  • 南非
  • 其他中東和非洲

第9章 主要進展

• 合約、夥伴關係、協作和合資企業
• 收購和合併
• 新產品發布
• 業務擴展
• 其他關鍵策略

第10章 公司簡介

• AB Sciex
• Abbott Laboratories
• Agilent Technologies Inc.
• Beckman Coulter, Inc.
• Biomedical Technologies Limited
• BioMerieux SA
• Bio Rad Laboratories, Inc.
• Danaher Corporation
• DH Tech. Dev. Pte. Ltd.
• DiaSorin SpA
• F. Hoffmann-La Roche Ltd
• Hologic Inc.
• Laboratory Corporation of America Holdings
• Ortho Clinical Diagnostics
• Qiagen NV
• Quest Diagnostics
• Siemens Healthineers AG
• Thermo Fisher Scientific

According to Stratistics MRC, the Global Endocrine Testing Market is accounted for $2.8 billion in 2023 and is expected to reach $5.5 billion by 2030 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

COVID-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory. Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market:

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

• Human Chorionic Gonadotropin Hormone Test
• Prolactin Test
• Progesterone Test
• Insulin Test
• Thyroid Stimulating Hormone Test
• Luteinizing Hormone Test
• Dehydroepiandrosterone Sulfate Test
• Estradiol Test
• Cortisol Test
• Testosterone Test
• Follicle Stimulating Hormone Test
• Other Test Types

Technologies Covered:

• Nucleic Acid Based
• Mass Spectroscopy
• Chromatography
• Immunoassay
• Other Technologies

End Users Covered:

• Clinical Laboratories
• Diagnostic Centers
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Endocrine Testing Market, By Test Type

• 5.1 Introduction
• 5.2 Human Chorionic Gonadotropin Hormone Test
• 5.3 Prolactin Test
• 5.4 Progesterone Test
• 5.5 Insulin Test
• 5.6 Thyroid Stimulating Hormone Test
• 5.7 Luteinizing Hormone Test
• 5.8 Dehydroepiandrosterone Sulfate Test
• 5.9 Estradiol Test
• 5.10 Cortisol Test
• 5.11 Testosterone Test
• 5.12 Follicle Stimulating Hormone Test
• 5.13 Other Test Types

6 Global Endocrine Testing Market, By Technology

• 6.1 Introduction
• 6.2 Nucleic Acid Based
• 6.3 Mass Spectroscopy
• 6.4 Chromatography
• 6.5 Immunoassay
• 6.6 Other Technologies

7 Global Endocrine Testing Market, By End User

• 7.1 Introduction
• 7.2 Clinical Laboratories
• 7.3 Diagnostic Centers
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Endocrine Testing Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AB Sciex
• 10.2 Abbott Laboratories
• 10.3 Agilent Technologies Inc.
• 10.4 Beckman Coulter, Inc.
• 10.5 Biomedical Technologies Limited
• 10.6 BioMerieux SA
• 10.7 Bio Rad Laboratories, Inc.
• 10.8 Danaher Corporation
• 10.9 DH Tech. Dev. Pte. Ltd.
• 10.10 DiaSorin SpA
• 10.11 F. Hoffmann-La Roche Ltd
• 10.12 Hologic Inc.
• 10.13 Laboratory Corporation of America Holdings
• 10.14 Ortho Clinical Diagnostics
• 10.15 Qiagen N.V.
• 10.16 Quest Diagnostics
• 10.17 Siemens Healthineers AG
• 10.18 Thermo Fisher Scientific

List of Tables

• Table 1 Global Endocrine Testing Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 3 Global Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 4 Global Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 5 Global Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 6 Global Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 7 Global Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 8 Global Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 9 Global Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 10 Global Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 11 Global Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 12 Global Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 13 Global Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 14 Global Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 15 Global Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 16 Global Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 17 Global Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 18 Global Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 19 Global Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 20 Global Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 21 Global Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 22 Global Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 23 Global Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 24 Global Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 25 Global Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 26 North America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 27 North America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 28 North America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 29 North America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 30 North America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 31 North America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 32 North America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 33 North America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 34 North America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 35 North America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 36 North America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 37 North America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 38 North America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 39 North America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 40 North America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 41 North America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 42 North America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 43 North America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 44 North America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 45 North America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 46 North America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 47 North America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 48 North America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 49 North America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 50 North America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 51 Europe Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 52 Europe Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 53 Europe Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 54 Europe Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 55 Europe Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 56 Europe Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 57 Europe Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 58 Europe Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 59 Europe Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 60 Europe Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 61 Europe Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 62 Europe Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 63 Europe Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 64 Europe Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 65 Europe Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 66 Europe Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 67 Europe Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 68 Europe Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 69 Europe Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 70 Europe Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 71 Europe Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 72 Europe Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 73 Europe Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 74 Europe Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 75 Europe Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 76 Asia Pacific Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Asia Pacific Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 78 Asia Pacific Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 79 Asia Pacific Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 80 Asia Pacific Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 81 Asia Pacific Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 82 Asia Pacific Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 83 Asia Pacific Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 84 Asia Pacific Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 85 Asia Pacific Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 86 Asia Pacific Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 87 Asia Pacific Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 88 Asia Pacific Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 89 Asia Pacific Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 90 Asia Pacific Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 91 Asia Pacific Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 92 Asia Pacific Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 93 Asia Pacific Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 94 Asia Pacific Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 95 Asia Pacific Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 96 Asia Pacific Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 97 Asia Pacific Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 98 Asia Pacific Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 99 Asia Pacific Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 100 Asia Pacific Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 101 South America Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 102 South America Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 103 South America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 104 South America Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 105 South America Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 106 South America Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 107 South America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 108 South America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 109 South America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 110 South America Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 111 South America Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 112 South America Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 113 South America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 114 South America Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 115 South America Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 116 South America Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 117 South America Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 118 South America Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 119 South America Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 120 South America Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 121 South America Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 122 South America Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 123 South America Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 124 South America Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 125 South America Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 126 Middle East & Africa Endocrine Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 127 Middle East & Africa Endocrine Testing Market Outlook, By Test Type (2021-2030) ($MN)
• Table 128 Middle East & Africa Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2021-2030) ($MN)
• Table 129 Middle East & Africa Endocrine Testing Market Outlook, By Prolactin Test (2021-2030) ($MN)
• Table 130 Middle East & Africa Endocrine Testing Market Outlook, By Progesterone Test (2021-2030) ($MN)
• Table 131 Middle East & Africa Endocrine Testing Market Outlook, By Insulin Test (2021-2030) ($MN)
• Table 132 Middle East & Africa Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2021-2030) ($MN)
• Table 133 Middle East & Africa Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2021-2030) ($MN)
• Table 134 Middle East & Africa Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2021-2030) ($MN)
• Table 135 Middle East & Africa Endocrine Testing Market Outlook, By Estradiol Test (2021-2030) ($MN)
• Table 136 Middle East & Africa Endocrine Testing Market Outlook, By Cortisol Test (2021-2030) ($MN)
• Table 137 Middle East & Africa Endocrine Testing Market Outlook, By Testosterone Test (2021-2030) ($MN)
• Table 138 Middle East & Africa Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2021-2030) ($MN)
• Table 139 Middle East & Africa Endocrine Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
• Table 140 Middle East & Africa Endocrine Testing Market Outlook, By Technology (2021-2030) ($MN)
• Table 141 Middle East & Africa Endocrine Testing Market Outlook, By Nucleic Acid Based (2021-2030) ($MN)
• Table 142 Middle East & Africa Endocrine Testing Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
• Table 143 Middle East & Africa Endocrine Testing Market Outlook, By Chromatography (2021-2030) ($MN)
• Table 144 Middle East & Africa Endocrine Testing Market Outlook, By Immunoassay (2021-2030) ($MN)
• Table 145 Middle East & Africa Endocrine Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 146 Middle East & Africa Endocrine Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 147 Middle East & Africa Endocrine Testing Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
• Table 148 Middle East & Africa Endocrine Testing Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 149 Middle East & Africa Endocrine Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 150 Middle East & Africa Endocrine Testing Market Outlook, By Other End Users (2021-2030) ($MN)